Navalign LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Navalign LLC’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,772	Closed	-$883K	–	129
2021 Q1	$883K	Buy	+5,772	New	+$893K	0.39%	56

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Navalign LLC's ALXN Position: Q2 2021 in Review

Navalign LLC sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 5,772 shares — an estimated $883K sold.

Navalign LLC first reported a position in ALXN in Q1 2021 and held it in 1 quarter. The position peaked at $883K in Q1 2021. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Navalign LLC reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Navalign LLC sold 5,772 Alexion Pharmaceuticals shares in Q2 2021, an estimated $883K.
Navalign LLC first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Navalign LLC's Alexion Pharmaceuticals position peaked at $883K in Q1 2021.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Navalign LLC's 13F filing for Q2 2021, filed 13 Aug 2021.